Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3400759 | 0.76 | SLC6A2 (0.38) | CHRM2CHRM4CHRM3SLC6A4 | |
| SCHEMBL13018511 | 0.76 | CHRM2 (0.38) | TSHRCHRM2CHRM4CHRM3SLC6A4 | |
| SCHEMBL3400952 | 0.75 | SLC6A2 (0.40) | CHRM2CHRM4CHRM3SLC6A4 | |
| SCHEMBL3400954 | 0.75 | SLC6A2 (0.40) | CHRM2CHRM4CHRM3SLC6A4 | |
| SCHEMBL3400949 | 0.75 | SLC6A2 (0.40) | CHRM2CHRM4CHRM3SLC6A4 | |
| SCHEMBL3398786 | 0.75 | SLC6A2 (0.37) | TSHRCHRM2CHRM4CHRM3SLC6A4 | |
| SCHEMBL3398740 | 0.75 | SLC6A2 (0.40) | CHRM2CHRM4CHRM3SLC6A4 | |
| SCHEMBL1897806 | 0.73 | CHRM2 (0.34) | CHRM2CHRM4CHRM3MEN1KMT2A | |
| SCHEMBL14552089 | 0.72 | APLNR (0.42) | TSHRCHRM2CHRM4CHRM3KMT2A | |
| SCHEMBL21621884 | 0.70 | APLNR (0.41) | CHRM2CHRM4CHRM3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150299090-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2015-10-22 | — | — | US | disclosed |
| US-20150299090-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2015-10-22 | — | — | US | disclosed |
| US-20150299090-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-2684861-A2 | Spiro compounds and pharmaceutical use thereof | Japan Tobacco Inc. (JP) | 2014-01-15 | — | — | EP | disclosed |
| US-20130109710-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2013-05-02 | — | — | US | disclosed |
| US-20130109710-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2013-05-02 | — | — | US | disclosed |
| US-20130109710-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2013-05-02 | — | — | US | disclosed |
| US-8299296-B2 | Spiro compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299296-B2 | Spiro compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299296-B2 | Spiro compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2012-10-30 | — | — | US | disclosed |
| EP-2508503-A1 | Spiro compounds and pharmaceutical use thereof | Japan Tobacco, Inc. (JP) | 2012-10-10 | — | — | EP | disclosed |
| EP-2202216-B1 | SPIRO-RING COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | JAPAN TOBACCO INC (JP) | 2012-06-27 | — | — | EP | disclosed |
| EP-2202216-A1 | SPIRO-RING COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Japan Tobacco Inc. (JP) | 2010-06-30 | — | — | EP | disclosed |
| US-20090170908-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20090170908-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20090170908-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170908-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | REN, PKD1, PKD2 | TSHR 2195/4885CHRM2 4478/4885CHRM4 4582/4885 |
| US-20150299090-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | REN, PKD1, PKD2 | TSHR 2195/4885CHRM2 4478/4885CHRM4 4582/4885 |
| US-20130109710-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | REN, PKD1, PKD2 | TSHR 2195/4885CHRM2 4478/4885CHRM4 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.